

Forward-Looking Statements

Certain information set forth in this presentation contains "forward-looking information", including "future-oriented financial information" and "financial outlook", under applicable securities laws (collectively referred to herein as forward-looking statements). Except for statements of historical fact, the information contained herein constitutes forward-looking statements and includes, but is not limited to, the (i) projected financial performance of the Company; (ii) completion of, and the use of proceeds from, the sale of the shares being offered hereunder; (iii) the expected development of the Company's business, projects, and joint ventures; (iv) execution of the Company's vision and growth strategy, including with respect to future M&A activity and global growth; (v) sources and availability of third-party financing for the Company's projects; (vi) completion of the Company's projects that are currently underway, in development or otherwise under consideration; (vi) renewal of the Company's current customer, supplier and other material agreements; and (vii) future liquidity, working capital, and capital requirements. Forward-looking statements are provided to allow potential investors the opportunity to understand management's beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment.

These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.

Although forward-looking statements contained in this presentation are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.

Do you dream about changing the world?

Us too.



Have you been waiting to get in on the ground floor of a BIG investment opportunity?

You just found it, ZEM Life Device.

Are you ok with one more child dying of anaphylaxis?

Are you ok with another father dying of a heart attack?

Are you ok with another daughter, son or friend dying of an opioid overdose?

WE AREN'T EITHER.

Before Penicillin

Widespread infections caused severe pain, limb amputations, and unnecessary death.

Before Defibrillator

Abnormal or stopped heart beats during sudden cardiac arrest, frantic CPR attempts, and unnecessary death.

Before ZEM Life Device

Panicked ER visits, mourning families, and unnecessary death from opioid overdoses, allergic reactions, heart attacks, asthma attacks, septic, cardiogenic and hemorrhagic shock, epilepsy, ketoacidosis, and more.

NO MORE...



A portable 24-hour emergency advanced life support system on your wrist.


Join us on the ground floor investment, as we bring this new life saving device to friends and loved ones around the world.



Opioid Overdoses are a BIG PROBLEM

SPOTLIGHT ON FENTANYL

Synthetic opioid **50 to 100 times** more powerful than morphine.



Nearly **impossible to detect** because it cannot be smelled or tasted.

OPIOIDS OVERDOSES ARE DEADLY



WE HAVE LIFE SAVING MEDICINE

Naloxone (also known as Narcan) prevents and reverses the deadly effects of an opioid overdose

but only if it's given in time.

It's not just Opioids, many conditions pose the risk of...

REFRACTORY VENTRICULAR TACHYCARDIA

PERFORMANCE SUPRA-VENTRICULAR
ENHANCEMENT TACHYCARDIA
MYOCARDIAI
THYRE

LONG QT SYNDROME
TORSADES DE POINTES
MYOCARDIAI
OINFARCTION

THYROID STORM

SYNDROME

ADAMS-STOKES SYNDROME CARDIOGENIC SHOCK

CRISIS TONIC-CLONIC

CONGESTIVE HEART FAILURE HEMORRHAGIC SHOCK SEIZURE

PREVENTABLE S CONTROL BRONCHOSPASM DIABETES A OF A CONTROL BRONCHOSPASM DIABETES A OF THE DISSECTION

SNAKE BITE (COBRAS, KRAITS, MAMBAS)

FPULSELESS VENTRICULAR TACHYCARDIA LIFE-THREATENING ASTHMA

DEATH



ANAPHYLACTIC SHOCK FERTILITY VENTRICULAR FIBRILLATION

ASYSTOLE/PEA ACUTE CORONARY SYNDROMES STATUS EPILEPTICUS ATRIO-VENTRICULAR HEART BLOCK SIDS

ANTICOAGULATION SUPRAVENTRICULAR TACHYCARDIA

REQUIREMENT

S NERVE GAS SCHIZOPHRENIA

ATRIAL FLUTTER HYPERGLYCEMIA

VENTRICULAR FIBRILLATION (

SEPTIC SHOCK

VENTRICULAR FIBRILLATION

ATRIAL FIBRILLATION PRE-TERM

POISONING

ORGANOPHOSPHATE

Millions of people die of these conditions when they don't get treatment in time.

IMMEDIATE danger requires IMMEDIATE response

When you or someone you love has a critical need for life-saving medication, every second counts.



Friend may or may not have the life saving medicine on hand

Patient is incapacitated and unable to move, think or communicate

Friend may not know what is needed, where to find it, when to give it, how to give it or how much to give.



Today, No Comparable Solutions Exist

	Epipen Other Auto Injectors	Trip to the Emergency Room	Vial of Medicine on Hand
Time	Fast	Slow	Fast
Cost	\$	999	§
Skill Needed	Medium	×	×
Tracks Vitals	×	Only Current	8
Automatic delivery	×	×	×
Portability		×	8
Supported Conditions	Only one Concern	All	Only one Concern
Repeatability	Single Use	Single Use	×



Multi Use



With Life Saving Features and Functionality:



Phone Calls, Apps

Automatic critical-need detection




Medical Record and Data availability



Automatic emergency services alert broadcasting



Automatic FDA approved medication delivery system



Love, Pain, and Purpose

ZEM Life Device Co was developed in the aftermath of impossible personal loss and an all too common tragedy:

23-year-old Zachary Ernest Muth was a loving son, a caring boyfriend, a student, a hard-working athlete. After a hockey injury and in need of a rotator cup replacement, **he took a pill** and went to sleep.

The pill was **laced with fentanyl**. If someone known, had someone been there and monitoring his vitals, he could have been saved by a simple dose of Narcan.



We are on a mission to make something good out of this to mitigate unexpected death.

We have the drive, tenacity, and experience to make ZEM Life Device a success and save lives.



Early in the morning of February 1st 2021, **Zachary Ernest Muth** passed away due to an **accidental overdose**.



Our Dedicated Team



Steve Muth

VP Business Development

- → Participated in over \$1 billion in capital raises.
- → Placeholder for 1-2 sentence bio



Joanna D Meston

President

- → MD of Anesthesiology
- → Successful Patents
- → Unique Chemical Engineering background



Zachary S Westerfield

VP Legal

- → PC
- → Litigation is 50 different cases
- → Placeholder for 1-2 sentence bio



Dave Palan, CPA

CFO

→ Placeholder for 1-2 sentence bio



Chris Sawyer VP

- → Engineering
- → BS ME
- → Placeholder for 1-2 sentence bio



Dr. Katherine Compton DO

Executive Director

- → A top 5280 and national recognized provider with CU Heath.
- → Placeholder for 1-2 sentence bio



Dan Ernest PC

Executive Director

- → Graduated at New York Law and a Yale university graduate.
- → Placeholder for 1-2 sentence bio



Daylan Executive Director

Andre

- → Head of new applications
- → Texas A&M

All directors are deeply committed and working on ZEM and are doing so for minimum wage.

Supported by Experienced Advisors



Andrew Graff Patents

- Leyendecker& Lemire, LLC
- Patent attorney

Dr. Anna Budde Market and Clinical Testing

- Head
 Anesthesiologist
 at University
 of Minnesota
- MD of Anesthesiology

Dr. Kevin BradyClinical studies

- Head of military Medical Applications
- ▶ Placeholder

Dr. Diane GillClinical studies

 Bio or information needed here



Key Partnerships





Prestigious Non-dilutive grant application writers

ZEM Life passed rigorous criteria to be admitted into their program.



"Grant Engine recommends ZEM Life Device Co. to investors seeking to support a company with the potential to make a significant impact on public health and safety. We are hopeful that ZEM Life Device Co. will innovate and lead in the field of medical device development."

Sam Tetlow



Regulatory compliance consulting services

FDA approval for device



"We have a very high interest in emerging technologies for saving lives from opioid overdoses and deaths. I look forward to continuing our productive relationship with ZEM Life. I urge full financial support for this life saving medical device application." Kelly Elliott RN, MS

Significant Traction in just 2.5 Years

2021

November 24

Idea created through difficulty and an unlikely event.

December

Engineering team determined that the functionality of the device idea could be feasible and implemented.

US Provisional application number 63-294,184 filed.

2022

January - November

Full patent and engineering feasibility and design.

December

Full patent application filed *US18/089,656*

2023

Secured QubeC.3

Development of device to meet FDA requirements

Secured Eminence Clinical

Research for FDA assistance

June

Received full patent pending status *US20230201463A1*

September

Filed FDA Breakthrough Device application

October

Secured CF Offering with Reg D company

December

Filed corporation in Delaware

2024

January

High level plan for FDA completion

Secured Grant Engine for grant capital

March

Filed additional patent addendums

April


Engaged all Executive Directors at Min wage

Filed SBIR Phase I application 4-24

May

Completed SEC - CR offering agreements

Lucrative Business Model



BUSINESS MODEL OPTIONS

- Branded cartridges licensing deals or partnerships with drug manufacturers
- Generic cartridges filled at the pharmacy
- User-refillable cartridges





FASTER TIME-TO MARKET

Because all drugs are approved and, on the market, there are **less strict FDA testing/approvals** required for the cartridges.

Expanded Product Offerings Planned

TYPES OF CARTRIDGES

"Jet" injection ·

Less invasive air injection

Needle injection •

1st Cartridge for Narcan will be this type for faster speed to market with FDA

High battery Cartridge

For travel, military needs

Reloadable Cartridge.

For daily use injections

TYPES OF DELIVERY

·· Automatic

(Triggered when body readings indicates a need)

Remote

Triggered by a 3rd Party

- → Doctor / patient
- → Parent / child
- → General / military personnel

Vast Market Opportunity

The potential applications are so vast, that is is hard to quantify all potential opportunities.

These are just a few.

OPIOIDS



80,411 Deaths Opioid overdose in 2021 **16.95M Doses of Naloxone** Distributed in the U.S. in 2021.

HEART ATTACK



695K DeathsIn the U.S.
from heart
disease
in 2021

16.3M Americansaged 20<
have Coronary
heart disease

ANAPHYLACTIC SHOCK



1 in 50 Americans

Have anaphylaxis, a life-threatening allergic reaction

SEPSIS



EPILEPSY





Future Opportunities

INFANTS



An infant device worn around the foot

SIDS

Apnea

Temperature monitoring

ANIMALS



An animal device with many opportunities

Endangered animals

Fertility for specialty breeding animals

Antibiotic deliver

MILITARY



An remotely monitored version worn by soldiers


Antidote for nerve gas

Morphine for pain and shock relief


Staying awake for long missions

Financial Projections

BASED ON THE THE FIRST CARTRIDGE: OPIATE (NARCAN)



Key Assumptions **\$20M**Expected in revenue in 2029







Seeking Funding to Launch

Develop partnerships for the medications

Development of device ready for full manufacturing

FDA approvals

- Watch approved as a medical device
- Leverage watch approval for more seamless cartridge approval

Funding will prepare us to go to market:



Fully working device



Initial cartridge(s)



Device is logged with FDA



Early marketing

Now is the Time to Invest

3 additional offerings--at higher valuations--planned in the next 2 years after meeting initial goals.

About the Offering

KEY OFFERING DETAILS

~40% of the company for \$5M.

Capitalization and dilution is minimal.

Convertible preferred.

Three different closes:

1 st Tranche	2 nd Tranche	3 th Tranche
3 warrants	2 warrants	1 warrant

YOUR INVESTMENT



\$50

Minimum investment

\$100,000

Maximum investment

*For larger investments, strategic partnership will be required for stock availability.

INVESTOR PERKS

\$100+

"I helped saved the world" Tshirt Other perks to **TBD**

\$250+

Access to the kick off party Other perks to TBD

\$1K+

TBD

Other Other perks to perks to TBD

\$2.5K+ \$25K+

> Other perks to TBD

About PALMS23 Foundation

Sharing this technology with the world through a HUMANITARIAN model.

This small residual income will be used to support the good work the foundation will do:

Opening a healing center for anyone dealing with devastating loss or pain.



Palms 23 Foundation is a nonprofit that owns a royalty for the IP smartwatch device and medication delivery system.



ZEM Life Device has the exclusive right to license the IP. Full office, manufacturing and warehouse availability with a Palms location.















Together we can stop or mitigate unexpected death in the world.

Or, please share this with someone else who can help.



Subscribe Now





Forward-Looking Statements

Certain information set forth in this presentation contains "forward-looking information", including "future-oriented financial information" and "financial outlook", under applicable securities laws (collectively referred to herein as forward-looking statements). Except for statements of historical fact, the information contained herein constitutes forward-looking statements and includes, but is not limited to, the (i) projected financial performance of the Company; (ii) completion of, and the use of proceeds from, the sale of the shares being offered hereunder; (iii) the expected development of the Company's business, projects, and joint ventures; (iv) execution of the Company's vision and growth strategy, including with respect to future M&A activity and global growth; (v) sources and availability of third-party financing for the Company's projects; (vi) completion of the Company's projects that are currently underway, in development or otherwise under consideration; (vi) renewal of the Company's current customer, supplier and other material agreements; and (vii) future liquidity, working capital, and capital requirements. Forward-looking statements are provided to allow potential investors the opportunity to understand management's beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment.

These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.

Although forward-looking statements contained in this presentation are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.